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Abstract
The purpose of the study was to evaluate the efficacy and safety of intravitreal anti-vascular endothelial growth
factor (anti-VEGF) in treatment of choroidal neovascularization (CNV) secondary to toxoplasmic retinochoroiditis in
five patients. After six months the CNV resolved as confirmed by fluorescein angiography and optical coherence
tomography (OCT) in all patients. The visual acuity improved from mean 20/400 to 20/80 and Central Macular
Thickness (CMT) decreased from 390 μm to 253 μm, which was maintained till the last follow-up visit.
Keywords: Anti-vascular endothelial growth factor; Choroidal
neovascularization; Toxoplasmosis
Introduction
Treatment modalities for choroidal neovascularization (CNV) due
to ocular toxoplasmosis include laser photocoagulation, surgery,
corticosteroids, and verteporfin therapy. Intravitreal injection of Anti-
vascular endothelial growth factor (anti-VEGF ) in the treatment of
CNV due to other conditions appears to be an effective and safe
therapeutic option. We report 5 cases of successful treatment with
anti-VEGF for symptomatic CNV due ocular toxoplasmosis.
Methods
The Isfahan University Medical Center approved this study. Our
study population consisted of 5 patients with CNV due to ocular
toxoplasmosis (3 women, 2 men) with a mean (SD) age of 27.2 (7.1)
years, all with documented notes suggested of clinical and serological
diagnosis of toxoplasmosis retinichoriditis and had been treated with
oral sulfadiazine and pyrimethamine, along with systemic steroids at
least 6 months before referral to our clinic.
All patients received a complete ophthalmologic evaluation. The
anterior chamber and vitreous cavity were quiet in all patients. No
signs suggestive of age-related macular degeneration were found.
Fluorescein (FA) criteria included evidence of leakage caused by CNV
(100% classic without an occult component) secondary to ocular
toxoplasmosis and presence of intraretinal or subretinal fluid
documented by optical coherence tomography (OCT). Intravitreal
anti-VEGF treatment was recommended for all patients (bevacizumab,
1.25 mg for 4 eyes and ranibizumab 0.5 mg for one eye).
Results
CNV was inactive in all eyes after Intravitreal anti-VEGF
treatments with an absence of leakage demonstrated by fluorescein
angiography, complete disappearance of exudative signs and reduction
of retinal thickness shown by OCT (Figure 1).
Figure 1: Fluorescein angiography (FA) and OCT before and after
treatment in 5 cases with choroidal neovascularization associated
with toxoplasmosis.
The mean follow-up was 14.4 months (range 6–24 months). Pre-
injection visual acuity measured 20/250 or worse in all eyes. According
to the last follow-up examination, visual acuity measured 20/30,
20/200, 20/200, 20/100 and 20/100 in eyes (Table 1). Mean Central
macular thickness (CMT) at baseline was 399 μm (380-410 μm). At the
last check, mean CMT reduction was 149 μm (65-175 μm), with a
mean thickness of 253 μm (range, 215-300 μm) (p=0.0002).
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No injection or drug-related complications, including
endophthalmitis, cataract, retinal detachment, glaucoma, or uveitis,
were observed.
Patient sex Age Initial VA
(Before
treatment)
Final VA eye Follow-up
(mo)
Injectio
n
MT
Pretreatm
ent
MT
Posttreat
ment
Investigation(s) Serology status
1 F 27 0.08 20/30 OD 24 m Avastin 395 300 FA, OCT IgG, positive; IgM,
negative
2 F 32 0.07 20/200 OS 6 m Avastin 410 250 FA, OCT IgG, positive; IgM,
negative
3 M 24 0.06 20/200 OD 12 m Avastin 380 215 FA, OCT IgG, positive; IgM,
negative
4 M 16 0.05 20/100 OS 15 m Avastin 400 250 FA, OCT IgG, positive; IgM,
negative
5 F 37 0.07 20/100 OS 15 m ranibizu
mab
410 235 FA,OCT IgG, positive; IgM,
negative
Table 1: Demographic and clinical characteristics of the patients in the study.
Discussion
CNV formation secondary to toxoplasmosis retinochoroiditis is a
rare event with a poor visual prognosis. Treatment modalities for CNV
secondary to toxoplasma retinochoroiditis include laser
photocoagulation, submacular surgery, PDT, and anti-VEGF agents
[1].
Because of the young age of our patients and occurrence of
permanent scotoma or a blind spot in the central visual field with laser
photocoagulation, this technique is not suitable for treatment. Surgery
can have its own complications and does not prevent recurrences.
Photodynamic therapy appears to be effective. Although, an early
recovery of visual acuity has been observed with PDT, multiple
treatments have been required [2].
In our small series of patients at 6- to 25-month follow up, leakage
diminished in all patients. A reduction of CMT was recorded in all
subjects. This change of retinal morphology is likely to be the result of
a combined antiexudative effect due to the decrease of vessel
permeability and the antiproliferative effect due to the inhibition of
further CNV growth following the VEGF blockage [1]. These
anatomical improvements were associated with concomitant increases
in VA. The mechanism of this outcome remains uncertain.
A previous case reports of CNV due to toxoplasmosis treated with
IVB show an improvement of the patient’s BCVA [3-5]. In our
patients, VA increased to normal levels and was preserved until the
end of follow-up. Unlike the repeated injections generally needed in
patients of CNV secondary to age-related macular degeneration [1] in
our study only one injection was required to achieve a good visual
outcome.
Our data seem to confirm the efficacy and safety of anti-VEGF
therapy in eyes with CNV secondary to ocular toxoplasmosis, although
we realize that the present study has some limitations, including the
limited number of patients and the absence of a standard protocol for
follow-up and treatment.
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